Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study - (the Amisulpride Study Group*

Author: Carriere P.   Bonhomme D.   Lemperiere T.  

Publisher: Elsevier

ISSN: 0924-9338

Source: European Psychiatry, Vol.15, Iss.5, 2000-08, pp. : 321-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content